| 2020 | PD-1 Blockade Reinvigorates Bone Marrow CD8 + T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
| CLINICAL CANCER RESEARCH |
| 2021 | PD-1 blockade-unresponsive human tumor-infiltrating CD8 + T cells are marked by loss of CD28 expression and rescued by IL-15 | CELLULAR & MOLECULAR IMMUNOLOGY |
| 2021 | PD-1-Expressing SARS-CoV-2-Specific CD8 + T Cells Are Not Exhausted, but Functional in Patients with COVID-19
| IMMUNITY |
| 2016 | PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
| SCIENTIFIC REPORTS |
| 2019 | PEGylated Magnetic Nano-Assemblies as Contrast Agents for Effective T2-Weighted MR Imaging
| Nanomaterials |
| 2020 | Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
| SCIENTIFIC REPORTS |
| 2022 | PERK prevents hepatic lipotoxicity by activating the p62-ULK1 axis-mediated noncanonical KEAP1-Nrf2 pathway
| REDOX BIOLOGY |
| 2020 | Peroxiredoxin 3 Has Important Roles on Arsenic Trioxide Induced Apoptosis in Human Acute Promyelocytic Leukemia Cell Line via Hyperoxidation of Mitochondrial Specific Reactive Oxygen Species
| MOLECULES AND CELLS |
| 2016 | Peroxiredoxin II Is Essential for Maintaining Stemness by Redox Regulation in Liver Cancer Cells | STEM CELLS |
| 2019 | Peroxiredoxin-mediated disulfide bond formation is required for nucleocytoplasmic translocation and secretion of HMGB1 in response to inflammatory stimuli
| REDOX BIOLOGY |
| 2008 | Peroxisome proliferator di-isodecyl phthalate has no carcinogenic potential in Fischer 344 rats | TOXICOLOGY LETTERS |
| 2019 | Personalized ablation of atrial fibrillation | NATURE BIOMEDICAL ENGINEERING |
| 2023 | Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2015 | PF-4708671, a specific inhibitor of p70 ribosomal S6 kinase 1, activates Nrf2 by promoting p62-dependent autophagic degradation of Keap1 | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS |
| 2020 | Pharmacogenomic Analysis Reveals CCNA2 as a Predictive Biomarker of Sensitivity to Polo-Like Kinase I Inhibitor in Gastric Cancer
| CANCERS |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck | CLINICAL CANCER RESEARCH |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
| ONCOTARGET |
| 2023 | Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2007 | Phellinus linteus inhibits inflammatory mediators by suppressing redox-based NF-κB and MAPKs activation in lipopolysaccharide-induced RAW 264.7 macrophage | JOURNAL OF ETHNOPHARMACOLOGY |
| 2023 | PHGDH preserves one-carbon cycle to confer metabolic plasticity in chemoresistant gastric cancer during nutrient stress | PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA |
